C4 Therapeutics Inc (CCCC) is destined for greater heights as its last quarter sales were 11,070 K

C4 Therapeutics Inc (NASDAQ: CCCC) kicked off on Friday, up 6.15% from the previous trading day, before settling in for the closing price of $14.82. Over the past 52 weeks, CCCC has traded in a range of $1.06-$8.42.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

A company in the Healthcare sector has jumped its sales by 17.88% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 0.61%. With a float of $38.33 million, this company’s outstanding shares have now reached $48.97 million.

C4 Therapeutics Inc (CCCC) Insider Updates

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of C4 Therapeutics Inc is 22.22%, while institutional ownership is 96.35%.

C4 Therapeutics Inc (CCCC) Performance Highlights and Predictions

In the latest quarterly report, which was put into the public domain on 9/29/2023, the organization reported -$0.55 earnings per share (EPS), higher than consensus estimate (set at -$0.66) by $0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.53 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 0.61% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.30% during the next five years compared to -46.29% drop over the previous five years of trading.

C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators

Take a look at C4 Therapeutics Inc’s (CCCC) current performance indicators. Last quarter, stock had a quick ratio of 7.39. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 14.89.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.75, a number that is poised to hit -0.69 in the next quarter and is forecasted to reach -2.29 in one year’s time.

Technical Analysis of C4 Therapeutics Inc (CCCC)

Let’s dig in a bit further. During the last 5-days, its volume was 2.1 million. That was inferior than the volume of 5.78 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 54.68%. Additionally, its Average True Range was 0.60.

During the past 100 days, C4 Therapeutics Inc’s (CCCC) raw stochastic average was set at 69.16%, which indicates a significant decrease from 82.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 93.90% in the past 14 days, which was lower than the 204.82% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $4.94, while its 200-day Moving Average is $3.28. However, in the short run, C4 Therapeutics Inc’s stock first resistance to watch stands at $6.38. Second resistance stands at $6.61. The third major resistance level sits at $7.00. If the price goes on to break the first support level at $5.76, it is likely to go to the next support level at $5.37. Assuming the price breaks the second support level, the third support level stands at $5.14.

C4 Therapeutics Inc (NASDAQ: CCCC) Key Stats

The company with the Market Capitalisation of 303.07 million has total of 49,281K Shares Outstanding. Its annual sales at the moment are 31,100 K in contrast with the sum of -128,180 K annual income. Company’s last quarter sales were recorded 11,070 K and last quarter income was -27,040 K.